Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: March 4th, 2011 - March 4th, 2012

Target Audience
This activity was developed for physicians, pharmacists, and other healthcare professionals practicing in a managed care environment.

Learning Objectives
Upon completion of this activity, the participant will be able to:

  • Explain the impact of key data presented at ASH 2010 on payers and providers in the treatment and management of multiple myeloma (MM)
  • Identify patient/disease-associated factors, as well as economic factors that may impact the choice of therapeutic agent, and formulate a management strategy  using a riskadapted approach to the treatment of MM
  • Construct informed treatment decisions for the purpose of improving the long-term outlook for patients with MM across the life-cycle of the disease
  • Discuss the future of MM treatment and the potential clinical, business, and regulatory changes that will affect the cost-value benefit design

Physician Credit Designation
The University of Cincinnati designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit  commensurate with the extent of their participation in this activity.

Pharmacists Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-11-004-H01-P.

Faculty Disclosures
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

John Fox, MD, and James T. Kenney, RPh, MBA, have nothing to disclose.

Linda Ritter, PhD, has nothing to disclose.

University of Cincinnati, the associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have  any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment  of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Estimated time to complete activity: 1 hour

Related Items
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Payer Perspective ASH 2011 Update: Strategies for Value-Based Care for Patients with Myelofibrosis
John Fox, MD, Michael J. Mauro, MD
Supplements published on April 30, 2012
Payer Perspective ASH 2011 Update: Multiple Myeloma Treatment Trends and Strategies for Value-Based Care
Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA
Supplements published on March 5, 2012
The Evolving Role of Outcomes and End Points in Evaluating Therapy for Hematologic Malignancies: Value-Driven Benefit Design and Utilization Management Strategies
Gary C. Yee, PharmD, FCCP, BCOP, James T. Kenney Jr, RPh, MBA, Michael Mauro, MD
Supplements published on July 15, 2011
ASH 2010 Update on Non-Hodgkin Lymphoma: Alignment of the Current Treatment Landscape and Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on February 28, 2011
Wellness and Prevention in Chronic Disease Consensus Statement
Gary M. Owens, MD, Nirav R. Shah, MD, MPH, FACP, Michael McLean, RPh, MPA, Kip Piper, MA, FACHE, Doug Burgoyne, PharmD, John Fox, MD, Stacie Heller, Wayne M. Lednar, MD, PhD, Lynne Rothney-Kozlak, Scott R. Taylor, RPh, MBA, F. Randy Vogenberg, RPh, PhD
Supplements published on September 30, 2010
The 32nd Annual San Antonio Breast Cancer Symposium Highlights: A Payer's and Pharmacist's Perspective
James T. Kenney Jr, RPh, MBA
Supplements published on February 15, 2010
Value-Based Oncology Benefit Design: Cost, Quality, and Access Considerations in Colorectal Cancer Care
Gary M. Owens, MD, John Fox, MD
Supplements published on April 30, 2009
Last modified: March 21, 2014